JESSICA INGRAM: Open Payments
NPI 1790259422 · ALABASTER, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$694 in 33 payments from 10 companies in 2025. Trend: 2023 $669 · 2024 $418 · 2025 $694
Food & beverage: $694
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 10 | $190 |
| Bayer Healthcare Pharmaceuticals Inc. | 8 | $136 |
| SCPHARMACEUTICALS INC. | 1 | $122 |
| Novartis Pharmaceuticals Corporation | 3 | $51 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 4 | $45 |
| Alnylam Pharmaceuticals Inc. | 2 | $39 |
| E.R. Squibb & Sons, L.L.C. | 2 | $37 |
| Abbott Laboratories | 1 | $25 |
| Novo Nordisk Inc | 1 | $25 |
| AstraZeneca Pharmaceuticals LP | 1 | $25 |
Products named: VYNDAQEL, Kerendia, FUROSCIX, LEQVIO, LifeVest, AMVUTTRA, CAMZYOS, MITRACLIP.
Industry payments across AL — which companies pay providers there.
